Justine E Campbell

Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC‐46)

J. Morton, V. Gordon, P. Reddell, 2020, Journal of veterinary internal medicine.

Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate

P. Reddell, R. Straw, J. Finlay, 2022, Frontiers in Veterinary Science.

Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors

V. Gordon, P. Reddell, S. Lowden, 2019, Front. Vet. Sci..

Intratumoural Treatment of 18 Cytologically Diagnosed Canine High-Grade Mast Cell Tumours With Tigilanol Tiglate

P. Reddell, T. D. De Ridder, G. Brown, 2021, Frontiers in Veterinary Science.

Recurrence‐free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate

P. Reddell, G. Brown, Chad M Johannes, 2020, Journal of veterinary internal medicine.

Tigilanol Tiglate-Mediated Margins: A Comparison With Surgical Margins in Successful Treatment of Canine Mast Cell Tumours

P. Reddell, T. D. De Ridder, G. Brown, 2021, Frontiers in Veterinary Science.

Wound formation, wound size, and progression of wound healing after intratumoral treatment of mast cell tumors in dogs with tigilanol tiglate

J. Morton, V. Gordon, P. Reddell, 2021, Journal of veterinary internal medicine.